Agents for alleviating symptoms accompanied by inflammation
The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.
1. A method for reducing a symptom from lipopolysaccharide-induced inflammation resulting from infection by bacteria which produce lipopolysaccharide, comprising administering to a person orally or parenterally, prior to the infection by the bacteria, an effective amount of human-type lactoferrin for a time and under conditions effective to reduce said symptom, wherein said symptom is accumulation of body fluid containing albumin in the abdominal cavity.
2. The method according to claim 1 , wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.
3. The method of claim 1 , wherein the lactoferrin is administered in the form of a tablet.
4. The method of claim 1 , wherein the lactoferrin is administered parenterally.
5. The method of claim 1 , wherein the lactoferrin is administered intravenously, intramucosally, percutaneously or intraperitoneally.
6. The method according to claim 1 , wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.
7. The method according to claim 6 , wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.
8. The method according to claim 1 , wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.
9. The method according to claim 8 , wherein the effective amount is 20 to 1000 mg/kg of body weight/day.
10. A method for reducing a symptom from lipopolysaccharide-induced inflammation resulting from infection by bacteria which produce lipopolysaccharide, comprising administering to a person orally or parenterally, prior to the infection by the bacteria, an effective amount of human-type lactoferrin for a time and under conditions effective to reduce said symptom, wherein said symptom is accumulation of albumin at in the abdominal cavity.
11. The method according to claim 10 , wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.
12. The method of claim 10 , wherein the lactoferrin is administered in the form of a tablet.
13. The method of claim 10 , wherein the lactoferrin is administered parenterally.
14. The method of claim 10 , wherein the lactoferrin is administered intravenously, intramucosally, percutaneously or intraperitoneally.
15. The method according to claim 10 , wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.
16. The method according to claim 15 , wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.
17. The method according to claim 10 , wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.
18. The method according to claim 17 , wherein the effective amount is 20 to 1000 mg/kg of body weight/day.